Proprietary R&D Programs

ACIES BIO is developing certain proprietary technologies (technology platforms, tools and novel bioactive compounds) and is looking for potential partnerships for co-development and/or licensing agreements.

• Dvelopment of Bacillus and Actinomyces based heterologous expression systems for production of secondary metabolites and heterologous proteins / enzymes
• Development of innovative gene tools for manipulation an efficient delivery of extremely large DNA fragments into expression hosts. These can also be used as a service to provide genetic / metabolic engineering of target strains, or to move biosynthetic gene clusters into suitable expression host for our customers
• Drug discovery: development of novel compounds focusing on anti-infective, anticancer, anti-inflammatory and neurodegenerative applications. ACIES BIO is keen to discuss potential licensing and/or co-development agreements with interested parties
• Co-development of biosimilar technologies in collaboration with a partner institution. A range of fully developed technologies for production of biosimilars is available for licensing